{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:15:10Z","timestamp":1779290110834,"version":"3.51.4"},"reference-count":10,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2003,5,1]],"date-time":"2003-05-01T00:00:00Z","timestamp":1051747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,5,1]],"date-time":"2003-05-01T00:00:00Z","timestamp":1051747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2003,5]]},"DOI":"10.1136\/ard.62.5.492","type":"journal-article","created":{"date-parts":[[2003,4,14]],"date-time":"2003-04-14T15:48:42Z","timestamp":1050335322000},"page":"492-493","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["Effects of interferon \u03b1 treatment on the clinical course of refractory Beh\u00e7et's disease: an open study"],"prefix":"10.1016","volume":"62","author":[{"given":"M","family":"\u00c7alg\u00fcneri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M A","family":"\u00d6zt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130","family":"Ertenli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Kiraz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u015e","family":"Apra\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z","family":"\u00d6zbalkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ard.62.5.492_bib1","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1600-0420.1997.tb00638.x","article-title":"Interferon alpha for ocular Beh\u00e7et\u2019s disease","volume":"75","author":"Pivetti-Pezzi","year":"1997","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1136\/ard.62.5.492_bib2","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/bjo.82.5.488","article-title":"Treatment of ocular symptoms of Beh\u00e7et\u2019s disease with interferon alpha 2a: a pilot study","volume":"82","author":"K\u00f6tter","year":"1998","journal-title":"Br J Ophthalmol"},{"key":"10.1136\/ard.62.5.492_bib3","first-page":"1938","article-title":"Interferon-alpha treatment of Beh\u00e7et\u2019s disease","volume":"25","author":"O\u2019Duffy","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.62.5.492_bib4","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1046\/j.1365-2796.1998.00159.x","article-title":"Efficacy and safety of systemic recombinant interferon-alpha in Beh\u00e7et\u2019s disease","volume":"243","author":"Georgiou","year":"1998","journal-title":"J Intern Med"},{"key":"10.1136\/ard.62.5.492_bib5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000246374","article-title":"Interferon alfa-2a in the treatment of Beh\u00e7et\u2019s disease","volume":"192","author":"Azizlerli","year":"1996","journal-title":"Dermatology"},{"key":"10.1136\/ard.62.5.492_bib6","first-page":"1098","article-title":"Systemic interferon alpha 2b treatment in Beh\u00e7et\u2019s syndrome","volume":"21","author":"Hamuryudan","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.62.5.492_bib7","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1001\/archderm.134.8.1010","article-title":"Treatment of Adamantiades-Beh\u00e7et disease with systemic interferon alfa","volume":"134","author":"Zouboulis","year":"1998","journal-title":"Arch Dermatol"},{"issue":"suppl","key":"10.1136\/ard.62.5.492_bib8","first-page":"S355","article-title":"Treatment of ocular Beh\u00e7et\u2019s disease (BD) with recombinant human interferon alpha 2a (rhIFN-\u03b12a): a three center pilot study [abstract]","volume":"41","author":"K\u00f6tter","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.62.5.492_bib9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00041327-200106000-00011","article-title":"Interferon-alpha 2a treatment of neuro-Beh\u00e7et disease","volume":"21","author":"Nichols","year":"2001","journal-title":"J Neuroophthalmol"},{"key":"10.1136\/ard.62.5.492_bib10","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1001\/archopht.1993.01090030068041","article-title":"Interferon-associated retinopathy","volume":"111","author":"Guyer","year":"1993","journal-title":"Arch Ophthalmol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724090241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724090241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.62.5.492","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T23:35:40Z","timestamp":1737243340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724090241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2003,5]]}},"alternative-id":["S0003496724090241"],"URL":"https:\/\/doi.org\/10.1136\/ard.62.5.492","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2003,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of interferon \u03b1 treatment on the clinical course of refractory Beh\u00e7et's disease: an open study","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.62.5.492","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2003 Copyright 2003 by Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}